These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 8827017

  • 1. Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    de Wit R, Verweij J, Bontenbal M, Kruit WH, Seynaeve C, Schmitz PI, Stoter G.
    J Natl Cancer Inst; 1996 Oct 02; 88(19):1393-8. PubMed ID: 8827017
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP, Anderson S, Wickerham DL, Clark R, Stoller R, Hamm JT, Stewart JA, Bear HD, Glass AG, Bornstein R.
    Am J Clin Oncol; 1994 Oct 02; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [Abstract] [Full Text] [Related]

  • 3. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 02; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 4. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L.
    Ann Oncol; 1994 Oct 02; 5(8):709-16. PubMed ID: 7826903
    [Abstract] [Full Text] [Related]

  • 5. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J.
    Clin Cancer Res; 1997 Dec 02; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [Abstract] [Full Text] [Related]

  • 6. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA, Marzec UM, Kelly AB, Cheung E, Tomer A, Nichol JL, Hanson SR, Stead RB.
    Blood; 1997 Jan 01; 89(1):155-65. PubMed ID: 8978288
    [Abstract] [Full Text] [Related]

  • 7. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
    Scinto AF, Ferraresi V, Campioni N, Tonachella R, Piarulli L, Sacchi I, Giannarelli D, Cognetti F.
    Ann Oncol; 1995 Sep 01; 6(7):665-71. PubMed ID: 8664187
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M, Siena S, Di Nicola M, Dodero A, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM.
    J Clin Oncol; 1996 Feb 01; 14(2):628-35. PubMed ID: 8636780
    [Abstract] [Full Text] [Related]

  • 11. Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
    Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA.
    J Natl Cancer Inst; 1997 Mar 05; 89(5):395-6. PubMed ID: 9060963
    [No Abstract] [Full Text] [Related]

  • 12. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H, Mulder NH, Willemse PH, van der Graaf WT, Sleijfer DT, Zijlstra JG, Elias M, Sibinga CT, Vellenga E, de Vries EG.
    Anticancer Res; 1995 Mar 05; 15(6B):2851-6. PubMed ID: 8669878
    [Abstract] [Full Text] [Related]

  • 13. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.
    Clin Breast Cancer; 2002 Oct 05; 3(4):268-75. PubMed ID: 12425755
    [Abstract] [Full Text] [Related]

  • 14. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
    Lalisang RI, Wils JA, Nortier HW, Burghouts JT, Hupperets PS, Erdkamp FL, Schouten HC, Blijham GH.
    J Clin Oncol; 1997 Apr 05; 15(4):1367-76. PubMed ID: 9193328
    [Abstract] [Full Text] [Related]

  • 15. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.
    J Clin Oncol; 1996 Nov 05; 14(11):2976-83. PubMed ID: 8918495
    [Abstract] [Full Text] [Related]

  • 16. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
    Yeung AW, Pang YK, Tsang YC, Wong SW.
    Cancer; 1994 Apr 01; 73(7):1960-70. PubMed ID: 7511042
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G.
    N Engl J Med; 1991 Jul 18; 325(3):164-70. PubMed ID: 1711156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.